Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur Urol. 2009 Mar;55(3):640-7. doi: 10.1016/j.eururo.2008.04.091. Epub 2008 May 9.

Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.

Author information

  • 1Urology Department, Val d'Ouest Hospital, 39 Chemin de la Vernique, 69130 Ecully, France. gfj-murat@club-internet.fr

Abstract

BACKGROUND:

Local occurrence of prostate cancer (PCa) after external beam radiation (EBRT) may benefit from definitive local therapy.

OBJECTIVE:

To evaluate the safety and efficacy of salvage high-intensity focal ultrasound (HIFU) in local PCa recurrence after EBRT and to determine prognostic factors for optimal patient selection.

DESIGN, SETTING, AND PARTICIPANTS:

Between 1995 and 2006, patients with a local PCa recurrence after EBRT were retrospectively included.

INTERVENTION:

All patients received salvage HIFU with the Ablatherm device.

MEASUREMENTS:

Prognostic factors (pre-EBRT risk group, androgen-deprivation [AD] use, pre-HIFU prostate-specific antigen [PSA], Gleason score and positive biopsy percentage) were studied in univariate and multivariate analyses. Progression was defined as positive biopsy and/or last PSA > nadir + 2 ng/ml and/or adjuvant therapy introduction. All complications were recorded.

RESULTS AND LIMITATIONS:

Some 194 HIFU sessions for 167 patients were performed. Local cancer control was achieved with negative biopsy results in 122 (73%) patients. The median PSA nadir was 0.19 ng/ml. The mean follow-up period was 18.1 mo (range: 3-121 mo). Seventy-four patients required no hormone therapy. The actuarial 5-yr overall survival rate was 84%. The actuarial 3-yr progression-free survival rate was significantly lower in three circumstances: (1) worsening of the pre-EBRT stage with 53%, 42%, and 25% for low-, intermediate-, and high-risk patients, respectively, (2) increase in the pre-HIFU PSA, and (3) use of AD during PCa management. In multivariate analyses, the risk ratio for intermediate- and high-risk patients were 1.32 and 1.96, respectively. The risk ratio was 2.8 if patients had received AD. No rectal complications were observed. Urinary incontinence accounted for 49.5% of the urinary sphincter implantations required in 11% of patients. This is a retrospective study in which the role of the PSA doubling time and the time until recurrence was not evaluated.

CONCLUSIONS:

Salvage HIFU is a curative treatment option for local relapse after EBRT with acceptable morbidity. Careful patient selection is imperative depending upon the aforementioned prognostic factors.

PMID:
18508188
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk